Ventrus (VTUS) Issues Results from Pivotal Phase 3 Trial of Iferanserin, Says Failed to Show Improvement from Therapy
Go back to Ventrus (VTUS) Issues Results from Pivotal Phase 3 Trial of Iferanserin, Says Failed to Show Improvement from Therapy| VENTRUS BIOSCIENCES (NASDAQ: VTUS) | Delayed: 1.45 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.45 | 52 Week High | $4.69 | |||
| Open | $6.60 | 52 Week Low | $0.85 | |||
| Day High | $1.45 | P/E | N/A | |||
| Day Low | $1.45 | EPS | $-0.99 | |||
| Volume | 247 | |||||
